**Decision-making ability in psychosis: A systematic review and meta-analysis of the magnitude, specificity and correlates of impaired performance on the Iowa and Cambridge Gambling Tasks.**

*Running head: Decision-making in psychosis*

Amanda Woodrow 1

Sarah Sparks2

Valeria Bobrovskaia2

Charlotte Paterson1

Philip Murphy1

Paul Hutton1

1School of Health and Social Care

Edinburgh Napier University

2School of Health in Social Science

University of Edinburgh

Corresponding author: Paul Hutton; Email: p.hutton@napier.ac.uk

Abstract word count: 250

Main text word count: 6107

**Abstract**

To identify factors which may help or hinder decision-making ability in people with psychosis, we did a systematic review and meta-analysis of their performance on the Iowa and Cambridge Gambling Tasks. Analysis of 47 samples found they had moderately poorer performance than healthy individuals (N=4264, g=-0.57, 95% CI -0.66 to -0.48). Few studies (k=8) used non-psychotic clinical comparator groups, although very low quality evidence (k=3) found people with bipolar disorder may perform better. Negative symptoms (k=13, N=648, r=-0.17, 95% CI -0.26, -0.07) and lower IQ (k=11, N=525, r= 0.20, 95% CI 0.29, 0.10), but not positive symptoms (k=10, N=512, r=-0.01, 95% CI -0.11, 0.08), each had small-moderate associations with poorer decision-making. Lower quality evidence suggested general symptoms, working memory, social functioning, awareness of emotional responses to information, and attentional bias towards gain are associated with decision-making, but not education, executive functioning or overall symptoms. Meta-regression suggested an inverse association between decision-making and depression severity (k=6, Q=6.41, R2 100%, p=0.01). Those taking first-generation (k=6, N=305, g=-0.17, 95% CI -0.40, 0.06, p=0.147) or low-dose antipsychotics (k=5, N=442, g=-0.19, 95% CI -0.44, 0.06, p=0.139) had unimpaired decision-making. Although meta-regression found no linear association between dose and performance, non-reporting of dose was common and associated with larger impairments (k=46, Q=4.71, R2 14%, p=0.03). Those supporting people with psychosis to make decisions, including treatment decisions, should consider the potential effect of these factors. Interventionist-causal trials are required to test whether reducing antipsychotic dose and treating anxiety and depression can improve decision-making in this group.

**Keywords**

*Psychosis, schizophrenia, decision making, Iowa gambling task, meta-analysis*

**Introduction**

Free and unimpaired decision-making is thought to be a necessary condition for self-governance and autonomy, concepts which are particularly important to people diagnosed with psychotic disorders such as schizophrenia (Stovell *et al.*, 2016), and are regarded as integral to their definitions of recovery (Law and Morrison, 2014). However recent meta-analyses have confirmed those receiving inpatient care are often judged to lack capacity to make their own decisions about treatment (Wang *et al.*, 2017), and that they generally make decisions based on less evidence than non-clinical individuals or people with non-psychotic mental health problems (Dudley et al. 2016). Effective interventions to support their decision-making are required (Larkin and Hutton, 2017; National Institute for Health and Social Care Excellence [NICE], 2018), however to develop these we first need to understand what factors help or hinder it.

To aid this, Larkin and Hutton recently conducted a systematic review and meta-analysis of 23 studies, and found that lower treatment decision-making capacity (‘capacity’) in psychosis is associated with greater psychotic symptom severity, fewer years of education, and lower verbal cognitive functioning, as well as lower insight, metacognitive ability, and anxiety (Larkin and Hutton, 2017). They also found preliminary evidence that provision of inpatient care (including antipsychotic treatment), information-simplification, shared decision-making and metacognitive training were each associated with improvements in capacity over time. However to develop a comprehensive theory of impaired capacity in psychosis, we need to establish what factors are *specifically* related to treatment decision-making in this group, and which affect their ability to make decisions generally. This, and the identification of other potential moderators of capacity, requires examination of the broader literature on decision-making in psychosis.

Decision-making is a complex process, and depends on the adequate operation of various cognitive, emotional and social factors. It is influenced by working memory capacity, intelligence, and information-processing heuristics, as well as external factors such as the quality of available decision-relevant information. According to Damasio’s ‘somatic marker hypothesis’, it also depends on a preserved ability to encode, store and retrieve emotion-stimuli associations (Damasio, Everitt and Bishop, 1996). This is thought to enable a person to quickly learn whether a particular stimuli involves risk or reward, and reactivation of these associations when faced with similar stimuli serves to implicitly influence conscious deliberation and choice. Disruption to these cognitive-emotional processes can be measured using the Iowa Gambling Task (IGT), with poor performance being evident in those who perform normally on other tests of intellectual and cognitive functioning yet have poor ‘real-world’ decision-making (Bechara *et al.*, 1994). For this reason, it is also regarded as a useful laboratory measure of practical decision-making ability (Buelow and Suhr, 2009; Must *et al.*, 2013), and the performance of people with psychosis on this task has now been studied extensively.

The IGT involves presenting participants with four decks of cards, who are then informed they will win or lose varying amounts of money with each card they choose and that their goal is to use their selections to win as much money as possible. Two decks provide small rewards and small losses, but provide greater overall reward if selected frequently, whereas the remaining two involve higher reward and higher losses, and incur an overall loss if favoured. Those who learn this and adjust their decision-making appropriately are likely to win more money than those who do not. Drawing on Buseyemer and Stout’s (2002) expectancy-valence (EV) model, Yechiam and colleagues found that poor performance on the IGT may involve difficulties in paying appropriate attention to either rewards or losses, difficulty learning or remembering past decision outcomes, or erratic responding (e.g., poor task engagement), depending on the underlying disorder (Busemeyer and Stout, 2002; Yechiam *et al.*, 2005). Unlike assessments of capacity, IGT performance does not depend on structured or unstructured clinical judgement, making it less susceptible to variance in clinician beliefs about illness and treatment, or variance in the working alliance between patients and clinicians. On the other hand, both IGT performance and capacity judgements depend on a person’s general ability to appreciate, understand and reason with decision-relevant information and both require a person to form and recall memories of the cognitive and emotional consequences of past decisions. In psychosis, having treatment decision-making capacity may often depend upon a preserved ability to form and recall memories of the costs and benefits of antipsychotic medication or inpatient care.

There are now dozens of studies of IGT performance in non-affective psychosis (‘psychosis’), however many are relatively small and therefore lack statistical power to detect clinically or theoretically relevant relationships. Although the IGT does not measure all processes involved in decision-making, or all types of decision-making, using meta-analysis to quantify the performance of people with psychosis on this task, and the factors which influence it, could overcome the power limitations of individual studies and deepen our understanding of what could be done to support their decision-making. Although Mukherjee and Kable (2014) performed a wide-ranging meta-analysis of IGT performance across various mental health conditions, only 14 psychosis samples were included, and no analysis of the correlates of their decision-making was performed (Mukherjee and Kable, 2014). The aim of the current review and meta-analysis is therefore to provide a definitive assessment of IGT decision-making performance in psychosis and the factors that may influence it, taking into account study and outcome quality.

**Methods**

*Protocol Registration*

The review protocol was registered in advance with the International Prospective Register of Systematic Reviews (PROSPERO), registration number CRD42016041241. Subsequent modifications are detailed in the supplement.

*Search strategy*

Electronic databases (PsychINFO, MEDLINE, EMBASE and Web of Science) were searched in June 2016 and March 2018 using the search terms (psychosis OR schizo\*) AND (decision making) AND (gambling task OR risk\* task OR gains task). Title lists from both searches were screened, and the full text reports of remaining articles were reviewed. The reference lists of relevant review articles were hand-searched. Two independent reviewers, overseen by a third, conducted the searches in parallel.

*Study selection and inclusion*

Published and unpublished English-language studies were eligible for inclusion if they reported usable cross-sectional or longitudinal data on the relationship between psychosis and decision-making as measured by the Iowa or Cambridge Gambling Tasks (CGT) (Bechara *et al.*, 1994; Rogers *et al.*, 1999), and if at least 50% participants in at least one group in the study had a diagnosis of non-affective psychosis (i.e. schizophrenia or schizophrenia-spectrum disorder, but not bipolar disorder).

*Outcomes*

We used IGT or CGT performance data to measure decision-making ability. The IGT, as described above, requires participants to complete 5 blocks of 20 trials, during which they are asked to maximise their financial gain. Both the IGT and CGT incorporate similar points-based or financial rewards and similar probabilistic learning parameters, and both require participants to consider the likelihood and magnitude of reward versus punishment. We compared the decision-making performance of participants with psychosis to healthy individuals and individuals with non-psychotic mental health problems. We examined group differences in performance according to antipsychotic type (second vs first generation), and group differences in the 3 parameters of the EV model of IGT performance (attention to gains, memory for recent outcomes, choice-consistency). We also examined the integrity of sample matching on IQ, gender and years of education, and within-group associations between decision-making and positive symptoms, negative symptoms, general symptoms, overall symptoms, working memory, executive functioning, IQ, years of education, antipsychotic dose (chlorpromazine equivalents), emotion (anxiety and depression), social outcomes and awareness of decision-making.

*Meta-regression*

Meta-regression was used to investigate whether group differences in decision-making performance were moderated by type of outcome extracted (IGT vs CGT; position in data extraction hierarchy), stage of illness (early psychosis vs chronic), proportion with schizophrenia, overall psychotic symptom severity, dose and type of antipsychotic, and group differences in depression, years of education, IQ and gender.

*Data extraction*

We decided in advance that the most representative measure of ‘good’ decision making on the IGT was the number of selections from advantageous decks. Data from the final 3 blocks (trials 41-100) were preferred, given evidence that blocks 1 and 2 should be regarded as a practice phase (Matsuzawa *et al.*, 2015), however if only overall data on blocks 1-5 were reported, then we used this. When only mean scores for the individual advantageous decks were reported, we calculated the mean of means. If this data were not reported, we used the ‘net score’, which is the number of selections from disadvantageous blocks subtracted from the number of selections from advantageous blocks. If no card choice information was provided, overall monetary gain or points accumulated throughout the task were used.

For meta-analyses of group differences, mean scores and standard deviations (SD) per group were extracted. Where there were two or more similar groups (e.g. psychosis non-smokers and psychosis smokers), these were combined using Cochrane Handbook recommended procedures (Higgins and Green, 2011). Where multiple mean scores were reported for one group (i.e. mean scores per block in the IGT) a simple average was computed. When only graphical representations of mean scores were provided, these were measured using Digitizeit software ([www.digitizeit.de](http://www.digitizeit.de)). Standard errors, confidence intervals or p-values were converted to SDs or effect sizes where required, again using Cochrane Handbook equations. Overall symptom ratings were converted to PANSS total scores where appropriate, using conversion charts (Leucht *et al.*, 2013; Samara *et al.*, 2014). Correlation coefficients were extracted or computed from available data.

*Assessment of study and outcome quality*

In line with previous meta-analyses of observational studies (Taylor et al. 2015; Dudley et al. 2016; Larkin & Hutton 2017), an adapted version of the Agency for Healthcare Research and Quality (AHRQ) tool was used to assess study quality. This measures a number of quality domains, including participant selection, matching of groups and use of a priori power calculations. Two researchers completed the assessment blind to overall results, and discrepancies were arbitrated by a third. The overall quality of each outcome, whether high, moderate, low or very low, was assessed using an adapted version of the Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach (Guyatt *et al.*, 2008). For univariate moderator analyses, we based our quality assessments on precision and risk of ecological bias, and for multivariate analyses we also assessed whether the conditional effect (or non-effect) of a moderator was likely to be an artefact of selective reporting of another variable.

*Analysis*

All analyses were conducted using Comprehensive Meta Analysis Version 3.3.07, when at least 3 studies reported usable data. A DerSimonian and Laird (1986) random-effects meta-analysis model was used (DerSimonian and Laird, 1986), since fixed-effects assumptions were unlikely to hold (Borenstein, 2009; Riley, Higgins and Deeks, 2011). For group differences and within-group correlations, pooled Hedges’s g and Pearson’s r were computed, respectively, along with 95% confidence intervals and p-values. Both were interpreted in line with Cohen’s (1988) established conventions (Hedges’s g; small = 0.2, moderate = 0.5, large = 0.8; Pearson’s r; small = 0.10, moderate = 0.30, large = 0.50) (Cohen, 1988). P-values less than 0.05 were interpreted as significant, but estimates close to this were downgraded for imprecision. Heterogeneity was assessed using the I2 statistic, and compared with thresholds specified in the Cochrane Handbook (<40% low; 75-100% considerable) (Higgins and Green, 2011). For analyses with at least 10 studies, the risk of publication bias was assessed using funnel plots, Egger’s test (Egger *et al.*, 1997) and the random-effects trim-and-fill procedure (Duval *et al.*, 2000).

**Results**

*Study selection*

As shown in the PRISMA diagram (Figure 1), the search returned 7072 results of which 6970 were excluded on the basis of title or abstract. The full text papers of 102 articles were examined, and a further 52 studies were excluded, mainly because an eligible decision-making task was not used. The remaining 50 studies provided data for 51 samples. Of these, 47 samples from 46 studies were included in the meta-analysis of differences in decision making performance between people with psychosis and healthy individuals. The rest were included in at least one other meta-analysis or reported individually. A table of included study characteristics and a list of excluded studies are provided in the supplement.

*Quality assessment*

In most studies, diagnoses were confirmed using DSM-IV (k=44) or ICD-10 criteria (k=3), with only 3 unclear or relying on chart diagnoses alone. There were relatively few instances of missing data. Although studies often reported attempting to match groups on demographic variables, participants with psychosis had significantly lower IQ than healthy individuals (k=31, -7.39 IQ points, 95% CI -9.23, -5.55), had spent less time in education (k=38,-1.6 years, 95% CI -1.98, -1.25) and were 13% more likely to be male (k=39, relative risk of being male=1.13, 95% CI 1.05, 1.21). Few studies provided pre-specified power calculations to justify their sample size, meaning there was a risk of results influencing decisions about recruitment discontinuation. Many used convenience samples, but few (k=2) used masked raters (Whitney *et al.*, 2004; Crespo-Facorro *et al.*, 2009). For these reasons, all meta-analytical estimates were downgraded for quality (see supplement for AHRQ assessments and Table 1 for GRADE ratings).

*Meta-analytical outcomes*

*Decision making performance: psychosis vs healthy individuals*

A meta-analysis of 47 comparisons from 46 studies (N psychosis=2276, N non-clinical=1988; Total N=4264) found that people with psychosis had moderately impaired decision-making ability compared to non-clinical individuals (g= -0.57, 95% CI -0.66, -0.48; I2 45%; moderate quality; Table 1; Figure 1). Funnel plots suggested a minor risk of publication bias, but Egger’s test was not significant (B = 0.10, SE = 0.57, p = 0.867) and trim-and-fill analysis did not change the estimate (adjusted g=-0.53, 95% CI -0.62, -0.44).

*Decision making performance: psychosis vs other clinical groups*

Eight studies compared people with psychosis to other clinical groups (Table 2). Very low quality evidence suggested they had lower decision-making performance than people with bipolar disorder (k=3, N=258, g=-0.35, 95% CI -0.60, -0.11, I2 0%). Very low quality evidence from single studies suggested their decision-making performance was significantly lower than people with depression (Da Silva, 2017), and similar to people diagnosed with either high-functioning autism (Zhang *et al.*, 2015) or dissocial personality disorder (Sedgwick, 2016). Their performance compared to people with obsessive-compulsive disorder (OCD) was non-significantly lower in one study (Whitney *et al.*, 2004), but significantly better in another (Cavallaro *et al.*, 2003).

*Expectancy-valence model parameters*

Six studies reported EV parameter data. Participants with psychosis were significantly more likely than healthy individuals to value rewards over losses (k=6, N=516, g=0.38, 95% CI 0.05, 0.70, I2 64%). There was trend-level evidence that they were more likely to base decisions on recent rather than past outcomes (k=6, N=516, g=0.30, 95% CI -0.04, 0.65, I2 68%) but no evidence that they responded more erratically (k=6, N=516, g=-0.19, 95% CI -0.57, 0.19, I2 74%). All estimates were very low quality.

*Task type & outcome*

Decision-making performance did not differ according to whether the IGT or CGT was used (k=47, Q=0.00, p=0.999, R2=0%; moderate), however it did vary according to the type of data selected (k=47, Q=20.86, p<0.001, R2=77%; high). Use of block 3-5 or block 1-5 data did not affect estimates, but net-derived estimates appeared to be significantly larger than non-net. However because the moderator analysis was unaffected by replacing all non-net estimates with net estimates but retaining their original categorisation (i.e., new net estimates stayed in their original non-net grouping) (k=46, Q=21.55, p<0.001, R2=78%), this was unlikely to explain these results. The moderator analysis also remained significant after removing studies reporting the least or second-least preferred data (k=41, Q=10.78, p=0.013, R2=58%).

*Stage of psychosis & proportion diagnosed with schizophrenia*

No association was found between decision-making performance and either the proportion of participants diagnosed with schizophrenia (k=43, Q=1.64, p=0.200, R2=18%; low) or stage of illness (early psychosis vs chronic) (k=47, Q=0.56, p=0.459, R2=5%; moderate), although only 4 early-psychosis samples were found.

*Psychotic symptoms*

No association between overall psychotic symptoms and decision-making was observed (k=6, r=-0.10, 95% CI -0.21, 0.02, I2=0%; very low quality), and PANSS total scores did not moderate group differences in decision-making, whether entered as a continuous (k=29, Q=0.01, p=0.925, R2=3%; moderate) or categorical variable, using empirically-derived thresholds for symptom severity (Leucht *et al.*, 2005) (k=30, Q=0.14, p=0.932, R2=0%; moderate). Studies not reporting overall symptom data reported significantly smaller decision-making impairments (k=47, Q=5.81, p=0.016, R2=43%; high; Figure 3). The estimates for studies providing and not providing this data were -0.65 (k=30, 95% -0.72, -0.58), and -0.41 (k=17, 95% CI -0.52, -0.29), respectively.

Within the psychosis groups, decision-making performance had a small-moderate inverse association with negative symptoms (k=13, N=648, r=-0.17, 95% CI -0.26, -0.07, I2 32%; moderate; Figure 4), a small association with general symptoms (k=5, N=169, r=-0.13, 95% -0.25, -0.00, I2=0%; low) and no association with positive symptoms (k=10, N=512, r=-0.01, 95% CI -0.11, 0.08; moderate; Figure 5). One small longitudinal study did not find that improvements in overall (N=25; r=0.17, 95% CI -0.24, 0.53), negative (r=0.19, 95% -0.23, 0.54), positive (r=0.18, 95% -0.23, 0.54) or general symptoms (r=0.15, 95% -0.26, 0.52) were significantly associated with improvements in decision-making performance (Premkumar *et al.*, 2011).

*Anxiety & Depression*

Differences in depression between healthy and psychosis groups were a significant moderator of decision-making performance in 6 studies (k=6, Q=6.41, p=0.01, R2=100%; low), and one study reported a significant association between poorer IGT performance and previous suicide attempts (N=50, r=0.36, 95% CI 0.10, 0.59) (Adan *et al.*, 2017). However no significant relationship between depression severity and performance was found by Hori et al (2014) (last 3 blocks combined; N=86, r=-0.16, 95% -0.36, 0.05) or Yip et al (2009) (N=42, r=0.05, 95% CI -0.26, 0.35) (Yip *et al.*, 2009; Hori *et al.*, 2014). In addition, Da Silva (2017) found that participants with psychosis and moderate depression had significantly lower IGT scores than non-psychotic participants with moderate depression (N=77, g=-0.62, 95% CI -1.07, -0.17) and Premkumar et al (2011) reported no improvement in decision-making performance (N=40, g=-0.15, 95% CI -0.76, 0.47, p=0.644) despite significant improvements in depression (N=40, g=-0.68, 95% -1.3, -.05, p=0.035) (Premkumar *et al.*, 2011; Da Silva, 2017). Brown et al 2015 reported a non-significant small negative correlation between anxiety and overall money earned on the IGT (N=59, r=-0.25, 95% CI -0.48, 0.00), whereas Newman (2008) reported a moderate and significant positive correlation between worry and IGT performance (N=70, r=0.29, 95% CI 0.06, 0.49) (Newman, 2008; Brown *et al.*, 2015). Participants in Highet (2014) did not have impaired decision-making compared to healthy individuals (N=56, g=-0.07, 95% -0.58, 0.45), despite being moderately anxious (Highet, 2014).

*Intelligence, education and gender*

Decision-making performance was significantly associated with IQ within the psychosis groups (k=11, N=525, r=0.20, 95% CI 0.29, 0.10, I2=8%; moderate; Figure 6) but not education (k=3, N=134, r=0.38, 95% CI -0.04, 0.69, I2=80%; very low quality), although the latter was based on heterogenous data from 3 small studies. Group differences in decision-making were not moderated by differences in either IQ (k=34, Q=0.89, p=0.346, R2=9%; moderate), education (k=38, Q=1.78, p=0.182, R2=5%; moderate), gender (k=42, Q=2.02, p=0.156, R2 15%; moderate) or matching of these variables (see Table 3).

*Working memory & executive functioning*

Decision-making was significantly associated with working memory (k=5, N=259, r=0.22, 95% CI 0.02, 0.41, I2 61%; very low quality), but not executive functioning ability (k=6, N=242, r=0.06, 95% CI -0.13, 0.26, I2=51%; very low quality) or perseveration (k=11, N=532, r=-0.07, 95% CI -0.23, 0.08, I2=64%; very low quality). However all estimates were inconsistent and imprecise, and there was some evidence of publication bias affecting the latter. Trim-and-fill analyses led to the imputation of 3 small studies, and the revised estimate suggested the possibility of a significant inverse relationship (r=-0.19, 95% CI -0.33, -0.03).

*Antipsychotic medication dose*

Limited but consistent evidence from 3 studies did not find an association between current antipsychotic dose and decision-making (N=171, r=-0.02, 95% CI -0.17, 0.13, I2=0%; low quality) and mean antipsychotic dose (chlorpromazine equivalents) did not moderate group differences in decision-making performance (k=19, Q=0.11, p=0.74, R2=3%; moderate). However dose as a categorical variable (none, low, medium, medium-high) did moderate estimates (k=19, Q=9.57, p=0.023, R2=62%; low). Participants in low dose studies had a non-significant and small impairment in decision-making performance (k=5, g=-0.19, 95% CI -0.44, 0.06), whereas significant impairments were observed in medium-dose studies (k=11, g=-0.52, 95% CI -0.67, -0.37), medium-high dose studies (k=2, g=-0.58, 95% CI -0.92, -0.24) and an antipsychotic-free study (k=1, g=-0.77, 95% CI -1.27, -0.28). Only 11 studies reported both dose and symptom data and multicollinearity meant we could not examine their combined effects in multivariate analysis.

Reporting of dose was a significant moderator (k=46, Q=4.71, p=0.030, R2=13%; moderate; Figure 7). The estimates for studies reporting and not reporting dose were -0.47 (k=19, 95% CI -0.59, -0.34) and -0.66 (k=27, 95% CI -0.78, -0.53), respectively. The proportion of participants who were antipsychotic-free did not moderate estimates (k=47, Q=1.04, p=0.309, R2=6%; low), however this was below 100% in only 4 studies.

*Antipsychotic medication type*

Participants taking SGAs did not have significantly reduced decision-making performance compared to those taking FGAs (FGAs vs SGAs; k=6, g=0.26, 95% CI -0.06, 0.58, I2=47%; very low quality), unless the single RCT was excluded (FGAs vs SGAs; k=5, g=0.36, 95% CI 0.68, 0.04, I2=32%). Compared to healthy individuals, those taking SGAs alone had a moderate impairment in decision-making (k=14, g=-0.56, 95% CI -0.78, -0.35, I2=71%; moderate quality), which was unaffected by excluding the single RCT (k=13, g=-0.61, 95% CI -0.82, -0.41, I2=66%). Those taking FGAs alone did not differ from healthy individuals in their decision-making performance (k=6, g=-0.17, 95% CI -0.40, 0.06, I2=0%; low quality) and excluding the single RCT also did not affect this (k=5, g=-0.19, -0.45, 0.08, I2=0%).

The antipsychotic-free study (Zhang *et al.*, 2015) was excluded from all moderator analyses of FGA and SGA use, and we divided studies into separate comparisons when decision-making performance according to antipsychotic type was provided (i.e., the control sample was divided equally between these new comparisons, as recommended by the Cochrane Handbook). The proportion of participants taking FGAs was a significant yet imprecise moderator of decision-making performance across the studies, with greater use associated with lower mean impairment (k=45, Q=3.86, p=0.049, R2=12%; low), and the proportion of participants taking SGAs had a non-significant but equally imprecise effect, with greater use non-significantly associated with greater impairment (k=45, Q=3.36, p=0.067, R2=11%; low). To test whether these findings reflect people with greater decision-making impairment being more likely to be prescribed SGAs when they were first introduced, we controlled for year of publication, but this had no effect. Neither association remained after controlling for PANSS total scores, but this was also the case when we didn’t control for PANSS total scores but did limit the univariate analysis to studies which reported both variables. Thus, it was not controlling for symptoms that removed the associations, but some other feature of the 28 samples for which both predictors were available.

*Social outcomes*

Limited evidence from 4 studies suggested there was a moderate association between IGT performance and social functioning (N=150; r=0.37, 95% CI 0.07, 0.51, I2 45%; very low quality). One study reported a small-moderate positive correlation between IGT performance and self-reported childhood abuse (N=70; r=0.24, 95% CI 0.01, 0.48), but not interpersonal victimisation (N=70; r=0.07, 95% CI -0.17, 0.30) (Newman, 2008). No association between decision-making and the social cognition domain of facial affect recognition was observed in another (N=39; -0.12, 95% CI -0.42, 0.20) (Lee *et al.*, 2009).

*Awareness and insight*

Large positive correlations between performance and participants’ subjective awareness of which decks were good and bad were reported by two studies [N=25; r=0.74, 95% CI 0.49, 0.88 (Cella *et al.*, 2012); N=19; r=0.66, 95% CI 0.29, 0.86 (Evans, Bowman and Turnbull, 2005; Turnbull *et al.*, 2006)]. One study did not a relationship with lower insight into illness (N=64; r=-0.18, 95% CI -0.41, 0.06) (Raffard *et al.*, 2011).

**Discussion**

*Does psychosis involve impaired decision-making, and is this specific to psychosis?*

Our primary aims were to establish whether people with psychosis demonstrate reduced decision-making performance on the Iowa and Cambridge Gambling Tasks, each of which are thought to measure the degree to which a person can use emotional information to successfully guide their decision-making during uncertainty, and to determine the magnitude, specificity and correlates of any observed impairment. The meta-analysis of data from over 4200 participants confirmed that people with psychosis do have moderately lower decision-making ability than healthy individuals, with the heterogeneity in this estimate relating to the size of the effect rather than its presence. However the Hedges’s g estimate of -0.57 corresponds to a Cohen’s U3 of 72%, which implies that 28% of people with psychosis are likely to have average or above-average performance on this task.

Although very low quality evidence from 3 studies suggested decision-making was somewhat poorer in non-affective psychosis than in bipolar disorder, few studies included non-psychotic clinical control groups. However, meta-analyses of various non-psychotic populations have reported impairments of comparable or greater magnitude to those we observed here. These range from moderate impairments in people with mood disorders who have attempted suicide (k=10, g=−0.65, 95% CI −1.03, −0.27) (Richard-Devantoy, Berlim and Jollant, 2014) and people with alcohol dependence (k=16, d=-0.58, 95% CI -0.90, -.27) (Kovács *et al.*, 2017) to moderate-large in eating disorders (anorexia k=16, g=-0.72, 95% CI -0.53, -0.92; bulimia k=9, g=-0.62, 95% CI -0.31, -0.93) (Guillaume *et al.*, 2015) to large in non-clinical obesity (k=6, d=-0.83, 95% CI 1.34, -0.33) (Rotge *et al.*, 2017) and gambling disorder (k=7, d=-1.03, 95% CI -1.56, -0.51) (Kovács *et al.*, 2017). However non-suicidal patients with mood disorders appear to have at best a small decrement in their performance (k=10, g=–0.24, 95% CI −0.53, 0.05) (Richard-Devantoy, Berlim and Jollant, 2014). Thus, impaired IGT performance is unlikely to be a specific characteristic of psychosis, but may instead affect a range of clinical groups.

*What factors help or hinder decision-making impairments in psychosis?*

The most reliable correlates of decision-making performance in psychosis (negative symptoms, IQ) were small-moderate in magnitude, whereas less reliable estimates ranged from small (general symptoms), to moderate (social functioning) to large (awareness of emotional responses). If shown to be causal, these factors should be taken into account when designing or adapting decision-support interventions with this group. For example, cognitive remediation therapy, which is already known to improve working memory, negative symptoms and social functioning in psychosis, could be adapted to include strategies to improve metacognitive awareness of decision-relevant information and aspects of cognitive processing which might affect this (Cella, Reeder and Wykes, 2015).

Few studies have examined or reported data on the role of emotional distress. However Newman’s (2008) finding of a positive correlation between worry and decision-making is consistent with emerging evidence elsewhere that greater anxiety in psychosis may be associated with better capacity to make decisions about treatment (Capdevielle *et al.*, 2009; Raffard *et al.*, 2013; Larkin and Hutton, 2017). However the decision-making performance of participants with psychosis was lower in studies where they were more depressed than healthy individuals, and other evidence suggests experimentally induced acute stress has a small-moderate negative effect on IGT decision-making in healthy individuals (Starcke and Brand, 2016).

We found no evidence that stage of illness, the proportion of people diagnosed with schizophrenia, positive symptoms, or overall symptom severity accounted for variance in decision-making performance. However some 38% of studies did not report overall symptom data and, compared to those that did, they reported significantly greater impairments in decision-making. The absence of a correlation between IGT performance and positive symptoms was consistent and the 95% confidence intervals excluded any significant associations. This was unexpected, given previous meta-analytical work has found that the presence of delusions in psychosis is associated with a small-moderate increase in the ‘jumping to conclusions’ (JTC) data-gathering bias (Dudley *et al.*, 2016), and that greater overall symptom severity is significantly associated with reduced treatment decision-making capacity (Larkin and Hutton, 2017). Theoretically, if positive symptoms are partly caused by aberrant salience, we might also expect this to disrupt decision-making performance in some way (Howes and Murray, 2014). Although many of the participants in the IGT studies fell within the ‘very mild’ to ‘mild’ categories of overall symptom severity, these findings do suggest that clinicians should not assume that positive symptom severity are a cause or consequence of impaired decision-making ability, and further research is required to investigate the relationship between relevant correlates of positive symptoms (i.e., impaired capacity, JTC bias, aberrant salience) and decision-making ability.

Working memory was correlated with decision-making performance, but executive functioning was not. Notwithstanding the risk of publication bias, these findings are consistent with the view that the IGT measures processes which are distinct from those assessed by traditional measures of executive functioning, such as the Wisconsin Card Sorting Task, as proposed by Bechara and colleagues in 1994 (Bechara *et al.*, 1994). However Yechiam and colleagues later proposed that reduced performance on the IGT may be caused by greater attention to rewards or losses (a ‘motivation’ parameter), problems in learning or remembering the consequences of past decisions (a ‘learning-rate’ parameter) or erratic and inconsistent decision-making, perhaps due to boredom or disinterest (a ‘choice-sensitivity’ parameter), with different disorders evidencing distinct patterns of impairment (Yechiam *et al.*, 2005). We found some evidence that people with psychosis do pay more attention to rewards than losses, relative to healthy individuals. Although it remains unclear whether they also have a greater preference for recent rather than past outcomes, there was no clear evidence that they engage in erratic or random responding.

Taken together, one possible explanation for our findings is that negative symptoms, which include anhedonia and affective blunting, reduce sensitivity to loss whereas working memory problems contribute to a diminished ability to remember decision-relevant information (Premkumar *et al.*, 2008), something which may be exacerbated by lower intellectual capacity. This would be consistent with the findings that both working memory and IQ are associated with poorer decision-making, as well as Cella and colleagues’ (2012) finding that reduced emotional responding to decks is associated with greater inattention to loss, which in turn is associated with poorer IGT performance (Cella *et al.*, 2012). It may also account for Newman’s finding that greater worry, which may involve heightened attention to loss, was associated with better IGT performance (Newman, 2008). It may be that negative symptoms, poor ‘metacognitive’ awareness of emotional responses and poor memory each serve to disrupt access to the somatic marker system which Damasio has argued is central to effective decision-making (Damasio, Everitt and Bishop, 1996). However we predict that both very low (i.e., anhedonia, affective blunting) and very high levels of emotion (i.e., emotional disorder) are likely to disrupt this process, albeit in different ways depending on the emotion involved. It is possible that a degree of worry and anxiety may be useful for increasing sensitivity to loss, but that acute levels of negative affect consume cognitive resources and motivation (Wells and Matthews, 1996). Evidence on the effects of acute stress on decision-making in healthy individuals is consistent with this (Starcke and Brand, 2016), as are the results of our meta-regression suggesting that decision-making performance was worse when the severity of depressed mood in the psychosis group was between 1 and 3 standard deviations greater than healthy individuals.

*Does antipsychotic medication help or hinder decision-making in psychosis?*

Our analysis of both antipsychotic dose and type was complicated by poor reporting. On the one hand, within-group data from 3 studies did not reveal a correlation between dose and decision-making, and dose did not account for variance in decision-making performance when analysed as a continuous variable in meta-regression. On the other hand, decision-making impairments were absent in low dose studies, whereas moderate impairments were observed in medium, medium-high dose studies and a single antipsychotic-free study, suggesting a possible curvilinear relationship. However given decision-making performance was significantly worse in the 60% of studies which did not report dose, there is considerable uncertainty about the true relationship. We also note that, although Zhang et al (2015) found a large impairment in IGT performance in antipsychotic-free first episode patients (Zhang *et al.*, 2015), an as-yet unavailable study reported that 26 antipsychotic-free first-episode patients performed normally in comparison to 19 healthy individuals before being prescribed antipsychotics, but a month later their performance relative to the same individuals was impaired (Bradford, 2015).

Decision-making impairments were also absent when those receiving FGAs alone were compared directly to healthy individuals, and a greater proportion of FGA monotherapy use was also associated with reduced decision-making impairment across the studies. One explanation for these findings is that participants who maintained their FGA monotherapy after SGAs were introduced already had relatively preserved decision-making performance, and were therefore less likely to switch to combination or SGA treatment to seek improvement. Supporting this, Crespo-Facorro et al (2009) randomised participants with first-episode psychosis to either FGA or SGA monotherapy and, after 2.5 months of treatment, neither group performed below healthy individuals (Crespo-Facorro *et al.*, 2009). Although scores at 12-months suggest the FGA group, contrary to the SGA and healthy control groups, had failed to improve in their performance, these figures contained data from 40% of participants who had switched to receiving SGAs, and no difference between the FGA and SGA groups was apparent in a per-protocol analysis excluding these participants. In addition, a small study by Bark et al, which we could not include in our meta-analyses because of unavailable variance data, compared the IGT performance of 8 patients diagnosed with catatonic schizophrenia, 19 diagnosed with paranoid schizophrenia and 26 healthy individuals (Bark *et al.*, 2005). Only the catatonic group had impaired IGT performance, however both psychosis groups were on low doses of typical antipsychotic medication.

Taken together, the above findings suggest it would be prudent to conduct further randomised controlled trials of the effect of high vs low antipsychotic medication dose and FGAs vs SGAs on decision-making ability in psychosis, also examining the potential consequences for treatment decision-making capacity. Further observational research is unlikely to resolve these issues, and if antipsychotic dose and type does alter decision-making – whether positively or negatively - this would have important clinical and legal implications, particularly for those with psychosis who currently have little choice over their treatment.

*Recommendations for future research*

We conducted this review primarily to help us develop our theoretical model of the factors that help or hinder treatment decision-making capacity (‘capacity’) in psychosis. There are obviously significant differences between decision-making performance on the IGT and capacity, however we note that clinical judgements of capacity appear to be much more affected by overall psychotic symptom severity than objective ratings of decision-making performance (Larkin and Hutton, 2017). Although overall symptoms have a moderate to large correlation with capacity (Larkin and Hutton, 2017), no clear relationship with IGT performance was found. Whether patient and clinician beliefs about illness, treatment and insight, not measured by the IGT, drive these differences is unclear. Whether judgements of capacity can be enhanced by administration of measures such as the IGT is also a matter for further research, but one that could have significant implications.

To aid with the development of interventions to support people with psychosis to make their own decisions, including decisions about treatment, we encourage researchers to routinely examine and report data on the effect of anxiety, depression and antipsychotic dose, and we recommend research on the potential relationship between psychosis-specific cognitive biases and decision-making, as well as longitudinal studies to prospectively examine risk factors for impaired decision-making in this group. However, to enable causal inference, researchers should consider conducting single-blind randomised experimental ‘interventionist-causal’ studies (Kendler and Campbell, 2009), where the effect of manipulating psychological, social or biological mechanisms on decision making is assessed directly.

*Limitations*

We pre-registered our review (Stewart, Moher and Shekelle, 2012) but to increase its usefulness we expanded its scope and assessed a number of additional outcomes. Meta-analyses of observational studies do not allow determination of cause and effect, but they can assess indicators of causality, such as the size, consistency and specificity of an association (Bradford-Hill, 1965), and they allow important gaps in our knowledge to be identified. We urge caution in the interpretation of some of our meta-regression estimates, particularly those which had low power, were affected by selective reporting, or had an increased risk of ecological bias, where between-study associations can diverge from within-study associations (Thompson and Higgins, 2002).

*Conclusion*

People with non-affective psychosis appear to make less effective decisions than healthy individuals, when this is assessed using the IGT or CGT. However, the moderate difficulties they have are comparable to those observed in other clinical groups, which casts doubt on their specificity. Nonetheless, clinicians seeking to support decision-making in this group should consider the potential role of negative symptoms, general symptoms, lower IQ, lower working memory, poorer social functioning and reduced awareness of emotional responses to decision-relevant information. The effect of high-dose antipsychotic treatment on decision-making should also be assessed, however this and the contribution of emotional disorders requires further research.

**Financial Support**

This research received no specific grant from any funding agency, commercial or not-for-profit sectors.

**Acknowledgements**

We would like to express our gratitude to anonymous reviewers for their important contributions to refining and improving this work.

**Conflict of interest**

Authors SS, AM, VB, CP and PM report no competing or conflictual interests. PH has been a co-investigator on research grants from the National Institute of Health Research to evaluate the efficacy of cognitive therapy for people with psychosis who are not taking antipsychotic medication and is a member of the committee which developed National Institute for Clinical and Social Care Excellence (NICE) guidelines on supporting decision-making for people who may lack mental capacity (Decision-Making and Mental Capacity; GID-NG10009).

**References**

Adan A, Capella MDM, Prat G, Forero DA, Lopez-Vera S and Navarro JF (2017) Executive functioning in men with schizophrenia and substance use disorders. Influence of lifetime suicide attempts. *PLoS One* **12**, 1.

Bark R, Dieckmann S, Bogerts B and Northoff G (2005) Deficit in decision making in catatonic schizophrenia: An exploratory study. *Psychiatry Research* **134**, 131–141.

Bechara A, Damasio A, Damasio H and Anderson S (1994) Insensitivity to future consequences following damange to human prefrontal cortex. *Cognition* **50,** 7–15.

Borenstein M, Hedges L, Higgins JPT and Rothstein H (2009) *Introduction to Meta-Analysis*. Wiley: Chichester.

Bradford-Hill A (1965) The Enviroment and Disease: Association or Causation? *Proceedings of the Royal Society of Medicine* **58,** 295–300.

Bradford L (2015) *The Effects of Atypical Antipsychotics on Implicit Reward Learning in Schizophrenia (Dissertation)*. Queens University.

Brown EC, Hack SM, Gold JM, Carpenter WT, Fischer BA, Prentice KP and Waltz JA (2015) Integrating frequency and magnitude information in decision-making in schizophrenia: An account of patient performance on the Iowa Gambling Task. *Journal of Psychiatric Research* **66-67**, 16–23.

Buelow MT and Suhr JA (2009) Construct validity of the Iowa Gambling Task. *Neuropsychology Review* **19**, 102–114.

Busemeyer JR and Stout JC (2002) A contribution of cognitive decision models to clinical assessment: Decomposing performance on the Bechara gambling task. *Psychological Assessment* **14**, 253–262.

Capdevielle D, Raffard S, Bayard S, Garcia F, Baciu O, Bouzigues I and Boulenger JP(2009) Competence to consent and insight in schizophrenia: Is there an association? A pilot study. *Schizophrenia Research* **108,** 272–279.

Cavallaro R, Cavedini P, Mistretta P, Bassi T, Angelone SM, Ubbiali A and Bellodi L (2003) Basal-corticofrontal circuits in schizophrenia and obsessive-compulsive disorder: A controlled double dissociation study. *Biological Psychiatry* **54,** 437–443.

Cella M, Dymond S, Cooper A and Turnbull OH (2012) Cognitive decision modelling of emotion-based learning impairment in schizophrenia: The role of awareness. *Psychiatry Research* **196,** 15–19.

Cella M, Reeder C, and Wykes T (2015) Lessons learnt? The importance of metacognition and its implications for Cognitive Remediation in schizophrenia. *Frontiers in Psychology* **6,** 1259.

Cohen J (1988) *Statistical Power Analysis for the Behavioral Sciences*. Lawrence Erlbaum Associates.

Crespo-Facorro B, Rodríguez-Sánchez JM, Pérez-Iglesias R, Mata I, Ayesa R, Ramirez-Bonilla M, Martínez-Garcia O and Vázquez-Barquero JL (2009) Neurocognitive effectiveness of haloperidol, risperidone and olanzapine in first-episode psychosis: A randomized controlled 1-year follow-up comparison. *Journal of Clinical Psychiatry* **70,** 717–729.

Damasio AR, Everitt BJ and Bishop D (1996) The Somatic Marker Hypothesis and the Possible Functions of the Prefrontal Cortex [and Discussion]. *Philosophical Transactions of the Royal Society B: Biological Sciences* **351,** 1413–1420.

Da Silva S (2017) *Deconstructing Motivation Deficits in Schizophrenia and Beyond (Disseration).* University of Toronto.

DerSimonian R and Laird N (1986) Meta-analysis in clinical trials. *Controlled clinical trials* **7,** 177–88.

Dudley R, Taylor P, Wickham S and Hutton P (2016) Psychosis delusions and the “Jumping to Conclusions” reasoning bias: A systematic review and meta-analysis. *Schizophrenia Bulletin* **42,** 652–665.

Duval S, Tweedie R, Taylor S and Tweedie R (2000) Trim and fill: A Simple Funnel Plot Based Method of Testing and Adjusting for Publication Bias in Meta-analysis. *Biometrics* **56,** 455–463.

Egger M, Davey Smith G, Schneider M and Minder C (1997) Bias in meta-analysis detected by a simple graphical test. *British Medical Journal* **315,** 629–634.

Evans CEY, Bowman CH and Turnbull OH (2005) Subjective awareness on the Iowa Gambling Task : The key role of emotional experience in schizophrenia. *Journal of Clinical and Experimental Neuropsychology* **27,** 656–664.

Guillaume S, Gorwood P, Jollant F, Van Den Eynde F, Courtet P and Richard-Devantoy S (2015) Impaired decision-making in symptomatic anorexia and bulimia nervosa patients: A meta-analysis. *Psychological Medicine* **45,** 3377–3391.

Guyatt GH, Oxman AD, Vist GE, Kunz R, Falck-Ytter Y, Alonso-Coello P, Schünemann HJ and GRADE Working Group (2008) GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. *British Medical Journal* **336,** 924-926.

Higgins JPT and Green S (2011) *Cochrane Handbook for Systematic Reviews of Interventions (Version 5.10)*. The Cochrane Collaboration..

Highet K (2014) *Thinking Matters: The Profile of Executive Functioning Associated with Cannabis Use in Schizophrenia and its Functional Outcome Correlates (Dissertation)*. Murdoch University.

Hori H, Yoshimura R, Katsuki A, Atake K and Nakamura J (2014) Relationships between brain-derived neurotrophic factor clinical symptoms and decision-making in chronic schizophrenia: data from the Iowa Gambling Task. *Frontiers In Behavioral Neuroscience* **8,** 417.

Howes OD and Murray RM (2014) Schizophrenia: An integrated sociodevelopmental-cognitive model. *The Lancet* **10,** 1677–1687.

Kendler KS and Campbell J (2009) Interventionist causal models in psychiatry: repositioning the mind–body problem. *Psychological Medicine* **39,** 881-887.

Kovács I, Richman MJ, Janka Z, Maraz A and Andó B (2017) Decision making measured by the Iowa Gambling Task in alcohol use disorder and gambling disorder: a systematic review and meta-analysis. *Drug and Alcohol Dependence* **181,** 152–161.

Larkin A and Hutton P (2017) Systematic review and meta-analysis of factors that help or hinder treatment decision-making capacity in psychosis. *British Journal of Psychiatry,* **211,** 205-215.

Law H and Morrison AP (2014) Recovery in psychosis: A delphi study with experts by experience. *Schizophrenia Bulletin* **40,** 1347–1355.

Lee SJ, Lee HK, Kweon YS, Lee CT and Lee KU (2009) The Impact of Executive Function on Emotion Recognition and Emotion Experience in Patients with Schizophrenia. *Psychiatry Investigation* **6,** 156-162.

Leucht S, Kane JM, Kissling W, Hamann J, Etschel E and Engel RR (2005) What does the PANSS mean? *Schizophrenia Research* **79,** 231–238.

Leucht S, Rothe P, Davis JM and Engel RR (2013) Equipercentile linking of the BPRS and the PANSS. *European Neuropsychopharmacology* **23,** 956–959.

Matsuzawa D, Shirayama Y, Niitsu T, Hashimoto K and Iyo M (2015) Deficits in emotion based decision-making in schizophrenia; a new insight based on the Iowa Gambling Task. *Progress in Neuro-Psychopharmacology and Biological Psychiatry* **57,** 52–59.

Mukherjee D and Kable J W (2014) Value-based decision making in mental illness: A meta-analysis. *Clinical Psychological Science* **2,** 767–782.

Must A, Horvath S, Nemeth VL and Janka Z (2013) The Iowa Gambling Task in depression - what have we learned about sub-optimal decision-making strategies? *Frontiers in Psychology*, **4,** 732.

National Institute for Health and Social Care Excellence (NICE) (2018) *Decision making and mental capacity (GID-NG10009): Draft guidelines*. National Institute for Health and Social Care Excellence.

Newman JM (2008) *The relationship between risk assessment and victimization in individuals with schizophrenia (Dissertation)*. Hofstra University.

Premkumar P, Fannon D, Kuipers E, Simmons A, Frangou S and Kumari V (2008) Emotional decision-making and its dissociable components in schizophrenia and schizoaffective disorder: A behavioural and MRI investigation. *Neuropsychologia* **46,** 2002–2012.

Premkumar P, Peters ER, Fannon D, Anilkumar AP, Kuipers E and Kumari V (2011) Coping styles predict responsiveness to cognitive behaviour therapy in psychosis. *Psychiatry Research* **187,** 354–362.

Raffard S, Capdevielle D, Gely-Nargeot MC, Attal J, Baillard A, Del-Monte J, Mimoun N, Boulenger JP and Bayard S (2011) Insight is not associated with insensitivity to future consequences in schizophrenia. *Psychiatry Research* **187,** 307–309.

Raffard S, Fond G, Brittner M, Bortolon C, Macgregor A, Boulenger JP, Gely-Nargeot MC and Capdevielle D (2013) Cognitive insight as an indicator of competence to consent to treatment in schizophrenia. *Schizophrenia Research* **144,** 118–121.

Richard-Devantoy S, Berlim M T and Jollant F (2014) A meta-analysis of neuropsychological markers of vulnerability to suicidal behavior in mood disorders. *Psychological Medicine* **44,** 1663–1673.

Riley RD, Higgins JPT and Deeks JJ (2011) Interpretation of random effects meta-analyses. *British Medical Journal* **342,** 549–549.

Rogers RD, Everitt BJ, Baldacchino A, Blackshaw AJ, Swainson R, Wynne K, Baker NB, Hunter J, Carthy T, Booker E, London M, Deakin JF, Sahakian BJ and Robbins TW (1999) Dissociable deficits in the decision-making cognition of chronic amphetamine abusers opiate abusers patients with focal damage to prefrontal cortex and tryptophan-depleted normal volunteers: Evidence for monoaminergic mechanisms. *Neuropsychopharmacology* **20,** 322–339.

Rotge JY, Poitou C, Fossati P, Aron-Wisnewsky J and Oppert JM (2017) Decision-making in obesity without eating disorders: a systematic review and meta-analysis of Iowa Gambling Task performances. *Obesity Reviews* **18,** 936–942.

Samara MT, Engel RR, Millier A, Kandenwein J, Toumi M and Leucht S (2014) Equipercentile linking of scales measuring functioning and symptoms: Examining the GAF, SOFAS, CGI-S, and PANSS. *European Neuropsychopharmacology* **24,** 1767–1772.

Sedgwick OL (2016) *The Contribution of Dissocial Personality Disorder to Cognition Emotion Processing and Clinical Outcome in Violent Men with Psychosis (Dissertation)*. Kings College London

Starcke K and Brand M (2016) Effects of stress on decisions under uncertainty: A meta-analysis. *Psychological Bulletin* **142,** 909–933.

Stewart L, Moher D and Shekelle P (2012) Why prospective registration of systematic reviews makes sense. *Systematic Reviews* **1,** 7.

Stovell D, Wearden A, Morrison AP and Hutton P (2016) Service users experiences of the treatment decision-making process in psychosis: A phenomenological analysis. *Psychosis: Psychological Social and Integrative Approaches* **8,** 311–323.

Taylor PJ, Hutton P and Wood L (2015) Are people at risk of psychosis also at risk of suicide and self-harm? A systematic review and meta-analysis. *Psychological Medicine* **45,** 911–926.

Thompson SG and Higgins JPT (2002) How should meta-regression analyses be undertaken and interpreted? *Statistics in Medicine* **21,** 1559–1573.

Turnbull OH, Evans CEY, Kemish K, Park S and Bowman CH (2006) A novel set-shifting modification of the Iowa Gambling Task: Flexible emotion-based learning in schizophrenia. *Neuropsychology* **20,** 290–298.

Wang SB, Wang YY, Ungvari GS, Ng CH, Wu RR, Wang J and Xiang YT (2017) The MacArthur Competence Assessment Tools for assessing decision-making capacity in schizophrenia: A meta-analysis. *Schizophrenia Research* **183,** 56-63.

Wells A and Matthews G (1996) Modelling cognition in emotional disorder: The S-REF model. *Behaviour Research and Therapy* **34,** 881–888.

Whitney KA, Fastenau PS, Evans JD and Lysaker PH (2004) Comparative neuropsychological function in obsessive-compulsive disorder and schizophrenia with and without obsessive-compulsive symptoms. *Schizophrenia Research* **69,** 75–83.

Yechiam E, Busemeyer JR, Stout JC and Bechara A (2005) Using cognitive models to map relations between neuropsychological disorders and human decision-making deficits. *Psychological Science* **16,** 973–978.

Yip SW, Sacco KA, George TP and Potenza MN (2009) Risk/reward decision-making in schizophrenia: A preliminary examination of the influence of tobacco smoking and relationship to Wisconsin Card Sorting Task performance. *Schizophrenia Research* **110,** 156–164.

Zhang L, Tang J, Dong Y, Ji Y, Tao R, Liang Z, Chen J, Wu Y and Wang K (2015) Similarities and Differences in Decision-Making Impairments between Autism Spectrum Disorder and Schizophrenia. *Frontiers in Behavioral Neuroscience* **9**, 259.

Table 1. Results of meta-analyses

| **Outcome** | **Number of included samples** | **Total N in psychosis group** | **Total N in control group** | **Effect size**  **(g or r unless specified)**  **(95% CI)** | **p-value for effect size** | **Heterogeneity (I2) for effect size** | **Quality**  **(GRADE)** |
| --- | --- | --- | --- | --- | --- | --- | --- |
| **Between-group comparisons** | | | | | | | |
| Decision-making performance: Psychosis versus non-clinical controls | 47 | 2276 | 1988 | -0.57 (-0.66, -0.48) | **<0.001** | 45% | Moderate  -1 quality |
| IQ: Psychosis versus non-clinical controls | 34 (g)  31 (WMD) | 1786 | 1623 | -0.59 (-0.73, -0.46) (g)  -7.39 (-9.23, -5.55) (WMD) | **<0.001 (g)**  **<0.001 (WMD)** | 71% (g)  81% (WMD) | High |
| Years of education: Psychosis vs non-clinical controls | 38 | 2002 | 1639 | -0.68 (-0.83, -0.53) (g)  -1.61 (-1.98, -1.25) (WMD) | **<0.001 (g)**  **<0.001 (WMD)** | 77% (g)  82% (WMD) | High |
| Gender (proportion male): Psychosis versus non-clinical controls | 39 (RR)  42 (RD) | 2121  (1431 male) | 1813  (1077 male) | 1.13 (1.05, 1.21) (RR)  0.07 (0.03, 0.12) (RD) | **0.002 (RR)**  **<0.001 (RD)** | 56% (RR)  45% (RD) | High |
| Decision-making performance: Psychosis versus Bipolar Disorder | 3 | 125 | 133 | -0.35 (-0.60, -0.11) | **0.005** | 0% | Very low  -2 quality  -1 imprecision |
| Decision-making performance: FGAs vs SGAs | 6 | 120 (FGAs) | 258 (SGAs) | 0.26 (-0.06, 0.58) | 0.115 | 47% | Very low  -1 quality  -1 imprecision  -1 inconsistency |
| Decision-making performance: SGAs vs healthy | 14 | 886 | 766 | -0.56 (-0.78, -0.35) | **<0.001** | 71% | Moderate  -1 quality |
| Decision-making performance: FGAs vs healthy | 6 | 120 | 185 | -0.17 (-0.40, 0.06) | 0.147 | 0% | Low  -1 quality  -1 imprecision |
| Attention to gain bias (insensitivity to loss): Psychosis vs healthy | 6 | 251 | 265 | 0.38 (0.05, 0.70) | **0.022** | 64% | Very low  -1 quality  -1 inconsistency  -1 imprecision |
| Memory bias for recent outcomes (learning-rate): Psychosis vs healthy | 6 | 251 | 265 | 0.30 (-0.04, 0.65) | 0.085 | 68% | Very low  -1 quality  -1 inconsistency  -1 imprecision |
| Choice-consistency (impulsivity or erratic responding): Psychosis vs healthy | 6 | 251 | 265 | -0.19 (-0.57, 0.19) | 0.326 | 74% | Very low  -1 quality  -1 inconsistency  -1 imprecision |
| **Within-group correlations** | | | | | | | |
| Overall symptoms | 6 | 291 | - | -0.10 (-0.21, 0.02) | 0.105 | 0% | Very low  -2 quality  -1 imprecision |
| Negative symptoms | 13 | 648 | - | -0.17 (-0.26, -0.07) | **0.001** | 32% | Moderate  -1 quality |
| Positive symptoms | 10 | 512 | - | -0.01 (-0.11,0.08) | 0.771 | 11% | Moderate  -1 quality |
| General symptoms | 5 | 253 | - | -0.13 (-0.25, -0.00) | **0.048** | 0% | Low  -1 quality  -1 imprecision |
| Intelligence | 11 | 525 | - | 0.20 (0.10, 0.29) | **<0.001** | 8% | Moderate  -1 quality |
| Education (years) | 3 | 134 | - | 0.38 (-0.04, 0.69) | 0.076 | 80% | Very low  -1 quality  -1 imprecision  -1 inconsistency |
| Working memory | 5 | 259 | - | 0.22 (0.02, 0.41) | **0.035** | 61% | Very low  -1 quality  -1 imprecision  -1 inconsistency |
| Executive functioning - perseveration | 11 | 532 | - | -0.07 (-0.23, 0.08) | 0.352 | 64% | Very low  -1 quality  -1 imprecision  -1 inconsistency  -1 publication bias |
| Executive functioning – overall performance | 6 | 242 | - | 0.06 (-0.13, 0.26) | 0.533 | 51% | Very low  -1 quality  -1 imprecision  -1 inconsistency |
| Antipsychotic dose | 3 | 171 | - | -0.02 (-0.17, 0.13) | 0.811 | 0% | Low  -1 quality  -1 imprecision |
| Social functioning | 4 | 150 | - | 0.30 (0.07, 0.51) | **0.011** | 45% | Very low  -2 quality  -1 imprecision |
|  |  |  |  |  |  |  |  |
| Note: Confidence interval (CI); Grading of Recommendations, Assessment, Development and Evaluations (GRADE); Hedges’s g (g); Weighted mean difference (WMD); Relative risk (RR); Risk difference (RD); First-generation antipsychotic (FGA); Second-generation antipsychotic (SGA); | | | | | | | |

Table 2. Decision-making performance: Psychosis vs non-psychosis mental health problems in individual studies

| **Study** | **Psychosis group** | **Comparator group** | **Total N in psychosis group** | **Total N in comparator group** | **Hedges’s *g***  **(95% CI)** | **p-value for *g*** |
| --- | --- | --- | --- | --- | --- | --- |
|  |  |  |  |  |  |  |
| Cavallero 2003 | Schizophrenia | Obsessive-Compulsive Disorder | 110 | 67 | 0.67 (0.36, 0.98) | **<0.001** |
| Whitney 2004 | Schizophrenia | Obsessive-Compulsive Disorder | 54 | 11 | -0.47 (-1.12, 0.17) | 0.151 |
| Brambilla 2015 | Schizophrenia | Bipolar Disorder | 70 | 70 | -0.30 (-0.63, 0.03) | 0.078 |
| Martino 2014 | Schizophrenia | Bipolar Disorder | 25 | 45 | -0.38 (-0.86, 0.11) | 0.132 |
| Caletti 2013 | Schizophrenia | Bipolar Disorder | 30 | 18 | -0.50 (-1.08, 0.09) | 0.096 |
| Da Silva 2017 | Schizophrenia | Depression | 39 | 38 | -0.62 (-1.07, -0.17) | **0.007** |
| Zhang 2015 | Schizophrenia (first-episode & antipsychotic-free) | High functioning autism (Asperger’s Syndrome) | 46 | 37 | 0.16 (-0.27, 0.59) | 0.458 |
| Sedgwick 2016 | Schizophrenia (forensic) | Dissocial Personality Disorder | 41 | 17 | -0.15 (-0.70, 0.41) | 0.609 |
|  |  |  |  |  |  |  |
| Note: Confidence interval (CI); Hedges’s g (g) | | | | | | |

Table 3. Meta-regression analyses of potential moderators of group differences in decision-making performance

| **Moderator** | **N samples** | **Groups (N samples)** | **Q-value** | **p-value** | **R2** | **Quality** |
| --- | --- | --- | --- | --- | --- | --- |
|  |  |  |  |  |  |  |
| Task type | 47 | IGT (43), CGT (4) | 0.00 | 0.999 | 0% | Moderate  - imprecision |
| Data extraction hierarchy | 47 | 1st (3), 2nd (24), 3rd (3), 4th (14), 5th (0), 6th (0), 7th (2), 8th (4) | 20.86 | **<0.001** | 77% | High |
| Data extraction hierarchy, using net scores where possible (k=5) | 47 | 1st (3), 2nd (24), 3rd (3), 4th (14), 5th (0), 6th (0), 7th (2), 8th (4) | 21.54 | **<0.001** | 78% | High |
| Year of publication | 47 | Year of publication (47) | 0.11 | 0.741 | 2% | High |
| Diagnosis | 43 | Proportion with schizophrenia (43) | 1.64 | 0.200 | 18% | Low  -1 ecological bias  -1 imprecision |
| Stage of illness | 47 | Early-psychosis (4), Established psychosis (43) | 0.56 | 0.459 | 5% | Moderate  -1 imprecision |
| Overall symptoms | 30 | PANSS mean total (30) | 0.01 | 0.925 | 3% | Moderate  -1 ecological bias |
| Symptom severity classification | 30 | Very mild (15), Mild (10), Moderate (5) | 0.14 | 0.932 | -14% | Moderate  -1 ecological bias |
| Overall symptom reporting | 47 | Reporting (30), Not reporting (17) | 5.81 | **0.016** | 43% | High |
| Depression differences | 6 | Depression severity, Hedges’s g (6) | 6.41 | **0.011** | 100% | Low  -1 ecological bias  -1 imprecision |
| Intelligence differences | 31-34 | IQ, mean difference IQ points (31)  IQ differences, Hedges’s g (34) | 0.00 (MD)  0.89 (g) | 0.946 (MD)  0.346 (g) | 0% (MD)  9% (g) | Moderate  -1 ecological bias |
| Intelligence matching | 34 | ≤ 3 point difference in mean IQ or g≤0.3 (9)  > 3 point difference in mean IQ or g>0.3 (25) | 0.03 | 0.856 | 1% | High |
| Education differences | 38 | Education, mean differences in years (38)  Education differences, Hedges’s g (38) | 1.15 (MD)  1.78 (g) | 0.283 (MD)  0.182 (g) | 4% (MD)  5% (g) | Moderate  -1 ecological bias |
| Education matching | 38 | ≤ 6 months difference in mean education duration (7)  > 6 months difference in mean education duration (31) | 0.00 | 0.948 | 0% | High |
| Gender differences | 42 | Proportion male, absolute risk difference (42)  Proportion male, relative risk difference (42) | 2.02 (RD)  2.22 (RR | 0.156 (RD)  0.137 (RR) | 15%  17% | Moderate  -1 ecological bias |
| Gender matching | 42 | ≥95% gender matching (16)  <95% gender matching (26) | 2.71 | 0.100 | 14% | High |
| Antipsychotic dose (continuous) | 19 | Mean CPZ equivalents (19) | 0.11 | 0.739 | 3% | Moderate  -1 ecological bias |
| Antipsychotic dose (categories) | 19 | None (1), Low (5), Medium (11), Medium-high (2) | 9.57 | **0.023** | 62% | Low  -1 ecological bias  -1 imprecision |
| Antipsychotic dose reporting | 46 | Reporting (19), Not reporting (27) | 4.71 | **0.030** | 14% | Moderate  -1 imprecision |
| Antipsychotic use | 47 | Proportion not taking antipsychotics (47) | 1.04 | 0.309 | 6% | Low  -1 ecological bias  -1 imprecision |
| FGA use | 45 | Proportion taking FGAs (45) | 3.86 | **0.049** | 12% | Low  -1 ecological bias  -1 imprecision |
| FGA use & year of publication | 45 | Proportion taking FGAs (45) | 3.92 (model) | 0.808 (year)  0.051 (FGA)  0.141 (model) | 0% year  12% (FGA)  12% (model) | Low  -1 ecological bias  -1 imprecision |
| FGA use & overall symptoms | 28 | Proportion taking FGAs (28) | 0.92 (model) | 0.638 (symptoms)  0.443 (FGA)  0.633 (model) | -1% (symptoms)  1% (FGA)  -11% (model) | Low  -1 ecological bias  -1 reporting bias |
| SGA use | 45 | Proportion taking SGAs (45) | 3.36 | 0.067 | 11% | Low  -1 ecological bias  -1 imprecision |
| SGA use & year of publication | 45 | Proportion taking SGAs (45) | 3.41 (model) | 0.812 (year)  0.069 (SGA)  0.182 (model) | 1% (year)  10% (SGA)  11% (model) | Low  -1 ecological bias  -1 imprecision |
| SGA use & overall symptoms | 28 | Proportion taking SGAs (28) | 0.92 (model) | 0.647 (symptoms)  0.444 (SGA)  0.633 (model) | 0% (symptoms)  0% (SGA)  -12% (model) | Low  -1 ecological bias  -1 reporting bias |
|  |  |  |  |  |  |  |
| Note: Iowa Gambling Task (IGT); Cambridge Gambling Task (CGT); Positive and Negative Syndrome Scale (PANSS); Mean difference (MD); Hedges’s g (g); Risk difference (RD); Relative risk (RR); Chlorpromazine (CPZ); First-generation antipsychotic (FGA); Second-generation antipsychotic (SGA. | | | | | | |